Sustained exendin-4 secretion through gene therapy targeting salivary glands in two different rodent models of obesity/type 2 diabetes.

Exendin-4 (Ex-4) is a Glucagon-like peptide 1 (GLP-1) receptor agonist approved for the treatment of Type 2 Diabetes (T2DM), which requires daily subcutaneous administration. In T2DM patients, GLP-1 administration is reported to reduce glycaemia and HbA1c in association with a modest, but significan...

Full description

Saved in:

Bibliographic Details
Main Authors:	Giovanni Di Pasquale, Ilaria Dicembrini, Laura Raimondi, Claudio Pagano, Josephine M Egan, Andrea Cozzi, Lorenzo Cinci, Andrea Loreto, Maria E Manni, Silvia Berretti, Annamaria Morelli, Changyu Zheng, Drew G Michael, Mario Maggi, Roberto Vettor, John A Chiorini, Edoardo Mannucci, Carlo M Rotella
Format:	article
Language:	EN
Published:	Public Library of Science (PLoS) 2012
Subjects:	Medicine R Science Q
Online Access:	https://doaj.org/article/b5a58b6ba4de46ae91ab1ee5fd254e6b
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Sustained exendin-4 secretion through gene therapy targeting salivary glands in two different rodent models of obesity/type 2 diabetes.

Similar Items